D3 PREMRNA PROCESSING IN CHRONIC PSYCHOSIS

慢性精神病中的 D3 前体 RNA 加工

基本信息

  • 批准号:
    2864068
  • 负责人:
  • 金额:
    $ 10.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-04-01 至 2001-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Adapted from applicant's abstract): The D2-class of dopamine receptors are targets for drugs with proven antipsychotic efficacy and have been repeatedly suggested as factors in the pathophysiology of schizophrenia. Although studies have failed to demonstrate a genetic link, studies on brain tissues obtained postmortem from long-term hospitalized patients with chronic psychosis suggest an abnormal posttranscriptional processing of dopamine D3-receptor-encoded pre-mRNA. This results in a decreased expression of D3 mRNA and an increased accumulation of an alternatively spliced, truncated D3-like mRNA, named D3nf. In order to pursue a more detailed investigation of the expression of D3 and D3nf mRNA and protein in postmortem tissues, and in order to begin to examine potential functional consequences of the enhanced D3nf-specific splicing of D3 pre-mRNA in chronic psychosis, it is proposed: (1) To perform RNase protection assays to determine the relative abundance of D3 and D3nf mRNA in defined anatomic regions of brains obtained postmortem from patients with chronic schizophrenia, bipolar affective disorders, and from controls. (2) To perform immunoprecipitation and immunoblot experiments with D3-specific monoclonal antibodies and a D3nf-specific polyclonal antiserum to determine whether (in the same anatomic regions) alterations in D3 and D3nf mRNA expression also result in corresponding changes in the expression of the respective proteins. (3) Furthermore, because co-expression of D3nf in stably D3-expressing rat GH3 cells increases the electrophoretic mobility of D3-immunoreactivity (from 50 kD to 180 kD), and because this co-expression appears to render a significant proportion of D3 receptors inaccessible to ligands, experiments on stably and inducibly D3, D3nf, and D3/D3nf expressing GH3 cells are proposed that aim at determining the protein composition of the D3nf-induced 180 kd D3-immunoreactivity, its posttranslational modifications, the kinetics of its formation, and its stability. In addition, radioligand binding studies are proposed to determine the Bmax of (3H)quinpirole binding of membranes of D3 and D3/D3nf-expressing cells. Finally, it will be tested in transfected polarized epithelial cells (MDCK) whether the membrane targeting of the D3 protein is altered in the presence of D3nf. Results of these studies are expected to provide insight into the extent to which the expression of D3 and D3nf mRNA and protein is altered in schizophrenia, and they will begin to elucidate the influence of D3nf expression of D3 receptor expression and function.
描述(改编自申请人的摘要):多巴胺的D2类 受体是具有已证实的抗精神病疗效的药物的靶点, 被反复建议作为因素的病理生理学 精神分裂症 尽管研究未能证明基因上的联系, 长期住院病人死后脑组织的研究 慢性精神病患者的基因转录后水平异常, 多巴胺D3受体编码的前mRNA的加工。 这导致 D3 mRNA表达减少, 选择性剪接的截短型D3样mRNA,命名为D3 nf。 为了 对D3和D3 nf mRNA的表达进行更详细的研究 和死后组织中的蛋白质,并且为了开始检查 增强的D3 nf特异性剪接的潜在功能后果, D3前体mRNA在慢性精神病中的表达,提出:(1)进行RNase 保护试验,以确定D3和D3 nf mRNA的相对丰度 从患有以下疾病的患者死后获得的大脑的定义解剖区域 慢性精神分裂症,双相情感障碍,并从控制。 (二) 为了用D3特异性抗体进行免疫沉淀和免疫印迹实验, 单克隆抗体和D3 nf特异性多克隆抗血清,以确定 是否(在相同的解剖区域)D3和D3 nf mRNA的改变 表达也会导致相应的表达变化, 各自的蛋白质。 (3)此外,由于D3 nf在细胞中的共表达, 稳定表达D3的大鼠GH 3细胞增加D3的电泳迁移率, D3-免疫反应性(从50 kD到180 kD),并且因为这种共表达 似乎使很大一部分D3受体无法进入, 配体,稳定和诱导D3,D3 nf和D3/D3 nf的实验 表达GH 3细胞,目的是确定蛋白质 D3 nf诱导的180 kd D3免疫反应性的组成,其 翻译后修饰,其形成的动力学,及其 稳定 此外,建议进行放射性配体结合研究, 测定D3膜的(3 H)喹吡罗结合的Bmax, D3/D3 nf表达细胞。 最后,将在转染的 极化上皮细胞(MDCK)是否膜靶向的D3 蛋白质在D3 nf的存在下发生改变。 这些研究的结果 预计将提供深入了解D3表达的程度 和D3 nf mRNA和蛋白质在精神分裂症中发生改变开始 为了阐明D3受体表达的D3 nf表达的影响, 功能

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CLAUDIA SCHMAUSS其他文献

CLAUDIA SCHMAUSS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CLAUDIA SCHMAUSS', 18)}}的其他基金

Epigenetic modulation of antidepressant efficacy
抗抑郁功效的表观遗传调节
  • 批准号:
    8706970
  • 财政年份:
    2013
  • 资助金额:
    $ 10.42万
  • 项目类别:
Epigenetic modulation of antidepressant efficacy
抗抑郁功效的表观遗传调节
  • 批准号:
    8582998
  • 财政年份:
    2013
  • 资助金额:
    $ 10.42万
  • 项目类别:
Genetic and environmental modulation of RNA editing
RNA编辑的遗传和环境调节
  • 批准号:
    7743836
  • 财政年份:
    2008
  • 资助金额:
    $ 10.42万
  • 项目类别:
Genetic and environmental modulation of RNA editing
RNA编辑的遗传和环境调节
  • 批准号:
    7991781
  • 财政年份:
    2008
  • 资助金额:
    $ 10.42万
  • 项目类别:
Genetic and environmental modulation of RNA editing
RNA编辑的遗传和环境调节
  • 批准号:
    7563296
  • 财政年份:
    2008
  • 资助金额:
    $ 10.42万
  • 项目类别:
5-HT2C-receptor expression and function in depression
抑郁症中 5-HT2C 受体的表达和功能
  • 批准号:
    6325053
  • 财政年份:
    2001
  • 资助金额:
    $ 10.42万
  • 项目类别:
5-HT2C-receptor expression and function in depression
抑郁症中 5-HT2C 受体的表达和功能
  • 批准号:
    6539139
  • 财政年份:
    2001
  • 资助金额:
    $ 10.42万
  • 项目类别:
5-HT2C-receptor expression and function in depression
抑郁症中 5-HT2C 受体的表达和功能
  • 批准号:
    6639197
  • 财政年份:
    2001
  • 资助金额:
    $ 10.42万
  • 项目类别:
5-HT2C receptor expression and function in depression
抑郁症中5-HT2C受体的表达和功能
  • 批准号:
    7120761
  • 财政年份:
    2000
  • 资助金额:
    $ 10.42万
  • 项目类别:
D3 pre-mRNA processing in chronic psychosis
慢性精神病中的 D3 mRNA 前体加工
  • 批准号:
    6832176
  • 财政年份:
    1997
  • 资助金额:
    $ 10.42万
  • 项目类别:

相似海外基金

Mechanisms of messenger RNA splicing and RNA processing regulation
信使RNA剪接和RNA加工调控机制
  • 批准号:
    10623834
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
Collaborative Research: Connecting the sequence logic of RNA splicing to nuclear localization
合作研究:将 RNA 剪接的序列逻辑与核定位联系起来
  • 批准号:
    2246530
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
    Standard Grant
Collaborative Research: Connecting the sequence logic of RNA splicing to nuclear localization
合作研究:将 RNA 剪接的序列逻辑与核定位联系起来
  • 批准号:
    2246531
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
    Standard Grant
Analysis on how RNA splicing factors change global gene expression patterns and regulate male fertility.
分析RNA剪接因子如何改变全局基因表达模式并调节男性生育能力。
  • 批准号:
    2882792
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
    Studentship
Aberrant RNA splicing in sporadic inclusion body myositis
散发性包涵体肌炎中的异常RNA剪接
  • 批准号:
    23K18260
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia
用于选择性靶向RNA剪接因子突变型白血病的合成内含子
  • 批准号:
    10722782
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
Cancer immune therapeutics targeting aberrant RNA splicing products
针对异常 RNA 剪接产物的癌症免疫疗法
  • 批准号:
    23H02688
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
RNA splicing regulation during alcohol withdrawal
酒精戒断过程中的 RNA 剪接调节
  • 批准号:
    10785159
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
Targeting Dysregulated RNA Splicing in Neurodegenerative Diseases
靶向神经退行性疾病中失调的 RNA 剪接
  • 批准号:
    10729566
  • 财政年份:
    2023
  • 资助金额:
    $ 10.42万
  • 项目类别:
Srsf3-mediated alternative RNA splicing in craniofacial development
Srsf3介导的颅面发育中的选择性RNA剪接
  • 批准号:
    10650417
  • 财政年份:
    2022
  • 资助金额:
    $ 10.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了